Clinical Trial Update: Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on Miravirsen in chronic hepatitis C patients who are null responders to pegylated interferon alfa plus ribavirin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Miravirsen (miravirsen)

Snippet

Sponsor: Santaris Pharma A/S | Conditions: Hepatitis C | Phase 2 | Status: UNKNOWN